254 related articles for article (PubMed ID: 36569209)
1. Synergistic effect of pyrvinium pamoate and posaconazole against
Li Y; Li S; Chen M; Xiao J; Fang H
Front Cell Infect Microbiol; 2022; 12():1074903. PubMed ID: 36569209
[TBL] [Abstract][Full Text] [Related]
2. Interactions between antifungals and everolimus against
Liang P; Song J; Liu Q
Front Cell Infect Microbiol; 2023; 13():1131641. PubMed ID: 37026056
[TBL] [Abstract][Full Text] [Related]
3. In vitro synergistic effect of minocycline combined with antifungals against Cryptococcus neoformans.
Tan L; Shi H; Chen M; Wang Z; Yao Z; Sun Y
J Mycol Med; 2022 Mar; 32(1):101227. PubMed ID: 34800920
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the relationship between drug susceptibility of Cryptococcus neoformans isolates and mortality in HIV-negative cryptococcal meningitis.
Su Z; Wei H; Liu J; Li C; Xu Z; Yuan D; Dai K; Peng F; Jiang Y
J Glob Antimicrob Resist; 2024 Mar; 36():167-174. PubMed ID: 38141953
[TBL] [Abstract][Full Text] [Related]
5. Interactions between triazoles and amphotericin B against Cryptococcus neoformans.
Barchiesi F; Schimizzi AM; Caselli F; Novelli A; Fallani S; Giannini D; Arzeni D; Di Cesare S; Di Francesco LF; Fortuna M; Giacometti A; Carle F; Mazzei T; Scalise G
Antimicrob Agents Chemother; 2000 Sep; 44(9):2435-41. PubMed ID: 10952592
[TBL] [Abstract][Full Text] [Related]
6. Comparative antifungal susceptibility analyses of Cryptococcus neoformans VNI and Cryptococcus gattii VGII from the Brazilian Amazon Region by the Etest, Vitek 2, and the Clinical and Laboratory Standards Institute broth microdilution methods.
Nishikawa MM; Almeida-Paes R; Brito-Santos F; Nascimento CR; Fialho MM; Trilles L; Morales BP; da Silva SA; Santos W; Santos LO; Fortes ST; Cardarelli-Leite P; Lázera MDS
Med Mycol; 2019 Oct; 57(7):864-873. PubMed ID: 30657975
[TBL] [Abstract][Full Text] [Related]
7. Synergistic Effect of Pyrvinium Pamoate and Azoles Against
Sun Y; Gao L; Zhang Y; Yang J; Zeng T
Front Microbiol; 2020; 11():579362. PubMed ID: 33224118
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of antifungal combination against Cryptococcus spp.
Reichert-Lima F; Busso-Lopes AF; Lyra L; Peron IH; Taguchi H; Mikami Y; Kamei K; Moretti ML; Schreiber AZ
Mycoses; 2016 Sep; 59(9):585-93. PubMed ID: 27135278
[TBL] [Abstract][Full Text] [Related]
9. Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole.
Espinel-Ingroff A; Aller AI; Canton E; Castañón-Olivares LR; Chowdhary A; Cordoba S; Cuenca-Estrella M; Fothergill A; Fuller J; Govender N; Hagen F; Illnait-Zaragozi MT; Johnson E; Kidd S; Lass-Flörl C; Lockhart SR; Martins MA; Meis JF; Melhem MS; Ostrosky-Zeichner L; Pelaez T; Pfaller MA; Schell WA; St-Germain G; Trilles L; Turnidge J
Antimicrob Agents Chemother; 2012 Nov; 56(11):5898-906. PubMed ID: 22948877
[TBL] [Abstract][Full Text] [Related]
10. Synergistic effect of the verapamil and amphotericin B against Cryptococcus neoformans.
Pereira TC; do Carmo PHF; de Menezes RT; de Oliveira HC; de Oliveira LD; Junqueira JC; Scorzoni L
Folia Microbiol (Praha); 2023 Dec; 68(6):999-1004. PubMed ID: 37950840
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo synergistic effects of hydroxychloroquine and itraconazole on Cryptococcus neoformans.
Wang X; Long X; Jia S; Zhu J; Zhou Z; Ahmed S; Jiang Y; Jiang Y
Folia Microbiol (Praha); 2023 Aug; 68(4):595-605. PubMed ID: 36753031
[TBL] [Abstract][Full Text] [Related]
12. [Antifungal susceptibility of clinically isolated invasive
Wan FF; Zhang M; Guo J; Wu WJ
Zhonghua Yu Fang Yi Xue Za Zhi; 2023 Oct; 57(10):1542-1549. PubMed ID: 37859369
[No Abstract] [Full Text] [Related]
13. Antifungal susceptibilities of Cryptococcus neoformans cerebrospinal fluid isolates and clinical outcomes of cryptococcal meningitis in HIV-infected patients with/without fluconazole prophylaxis.
Manosuthi W; Sungkanuparph S; Thongyen S; Chumpathat N; Eampokalap B; Thawornwan U; Foongladda S
J Med Assoc Thai; 2006 Jun; 89(6):795-802. PubMed ID: 16850679
[TBL] [Abstract][Full Text] [Related]
14. Reduced Susceptibility to Azoles in Cryptococcus gattii Correlates with the Substitution R258L in a Substrate Recognition Site of the Lanosterol 14-α-Demethylase.
Carvajal SK; Melendres J; Escandón P; Firacative C
Microbiol Spectr; 2023 Aug; 11(4):e0140323. PubMed ID: 37341584
[TBL] [Abstract][Full Text] [Related]
15. In vitro antifungal activities of amphotericin B, 5-fluorocytosine, fluconazole and itraconazole against Cryptococcus neoformans isolated from cerebrospinal fluid and blood from patients in Serbia.
Trpković A; Pekmezović M; Barać A; Crnčević Radović L; Arsić Arsenijević V
J Mycol Med; 2012 Sep; 22(3):243-8. PubMed ID: 23518082
[TBL] [Abstract][Full Text] [Related]
16.
Sun Y; Gao L; Yuan M; Yuan L; Yang J; Zeng T
Front Cell Infect Microbiol; 2020; 10():576975. PubMed ID: 33194816
[TBL] [Abstract][Full Text] [Related]
17. Adaptation to Fluconazole via Aneuploidy Enables Cross-Adaptation to Amphotericin B and Flucytosine in Cryptococcus neoformans.
Yang F; Gritsenko V; Lu H; Zhen C; Gao L; Berman J; Jiang YY
Microbiol Spectr; 2021 Oct; 9(2):e0072321. PubMed ID: 34585947
[TBL] [Abstract][Full Text] [Related]
18. Impact of iron chelators on growth and expression of iron-related genes of Cryptococcus species.
Chayakulkeeree M; Tangkoskul T; Waywa D; Tiengrim S; Pati N; Thamlikitkul V
J Mycol Med; 2020 Apr; 30(1):100905. PubMed ID: 31706700
[TBL] [Abstract][Full Text] [Related]
19. Susceptibility profile and epidemiological cut-off values of Cryptococcus neoformans species complex from Argentina.
Córdoba S; Isla MG; Szusz W; Vivot W; Altamirano R; Davel G
Mycoses; 2016 Jun; 59(6):351-6. PubMed ID: 26865081
[TBL] [Abstract][Full Text] [Related]
20.
Sun Y; Tan L; Yao Z; Gao L; Yang J; Zeng T
Microbiol Spectr; 2022 Feb; 10(1):e0200721. PubMed ID: 35019705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
